COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01938833
Recruitment Status : Terminated (Closed by Sponsor)
First Posted : September 10, 2013
Results First Posted : September 29, 2017
Last Update Posted : December 28, 2017
Celgene Corporation
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )

Brief Summary:
This phase I/II trial studies the side effects and best dose of romidepsin when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well they work in treating patients with metastatic inflammatory breast cancer. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving romidepsin and paclitaxel albumin-stabilized nanoparticle formulation may be an effective treatment for inflammatory breast cancer.

Condition or disease Intervention/treatment Phase
HER2-negative Breast Cancer Inflammatory Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer Drug: Romidepsin Drug: Abraxane Phase 1 Phase 2

Detailed Description:


  1. To assess the safety of the combination of romidepsin plus Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) delivered weekly. (Phase I)
  2. To determine the maximum tolerated dose (MTD) of romidepsin with full dose weekly Abraxane to define a recommended phase II doses of the combination. (Phase I)
  3. To assess the progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2) negative, newly diagnosed metastatic inflammatory breast cancer treated with the combination of romidepsin and Abraxane. (Phase II)


  1. To assess the safety and tolerability of the combination of romidepsin and Abraxane.
  2. To determine the adverse event profile of the combination of romidepsin and Abraxane.
  3. To assess the overall response rate (ORR) and clinical benefit rate (CBR) in patients with newly recurrent inflammatory breast cancer (IBC) treated with the combination of romidepsin and Abraxane.

OUTLINE: This is a phase I, dose-escalation study of romidepsin followed by a phase II study.

Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer
Actual Study Start Date : April 2014
Actual Primary Completion Date : August 18, 2016
Actual Study Completion Date : December 8, 2016

Arm Intervention/treatment
Experimental: Treatment (Romidepsin and Abraxane)
Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Romidepsin
Other Names:
  • Istodax
  • FK228
  • FR901228
  • Depsipeptide

Drug: Abraxane
Other Names:
  • Protein-bound paclitaxel
  • Paclitaxel albumin-stabilized nanoparticle formulation

Primary Outcome Measures :
  1. Maximum-Tolerated Dose of Romidepsin (Phase I) [ Time Frame: 28 days ]
    Determined according to incidence of dose-limiting toxicity, graded using the National Cancer Institute (NCI) CTCAE version 4.0

  2. Progression-Free Survival (PFS) [ Time Frame: The duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years ]

Secondary Outcome Measures :
  1. Incidence of Adverse Events, Graded According to NCI CTCAE Version 4.0 [ Time Frame: Up to 30 days ]
    Summary tables of grade 2, 3, and 4 toxicities, adverse events (AE), and serious adverse events (SAE) will be generated at the conclusion of the study as well as at the conclusion of phase I study and after 15 patients have been collected on at the interim evaluation time point of the phase 2 part of the study.

  2. Overall Response Rate (ORR) [ Time Frame: Up to 5 years ]
    The 95% confidence intervals should be provided.

  3. Clinical Benefit Rate (CBR) [ Time Frame: Up to 5 years ]
    The 95% confidence intervals should be provided.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have histologically or cytologically confirmed breast carcinoma with a clinical diagnosis of IBC based on the presence of inflammatory changes in the involved breast, such as diffuse erythema and edema (peau d'orange), with or without an underlying palpable mass involving the majority of the skin of the breast. Pathological evidence of dermal lymphatic invasion should be noted but is not required for diagnosis.
  2. Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 as described in detail in section 11.0 or non-measurable tumors
  3. Patients must have demonstrated metastatic disease and not received >2 lines of systemic therapy for metastatic disease
  4. Age > 18 years
  5. ECOG performance status 0, 1 or 2
  6. Patients must have normal organ and marrow function as defined below: a) Leukocytes > 2,500/mcL b) Absolute neutrophil count > 1,500/mcL c) Hemoglobin > 9 g/dl d) Platelets > 100,000/mcL e) Total bilirubin < 1.5 mg/dl f) AST/ALT (SGOT/SGPT) < 2.5 x ULN g) Alkaline Phosphatase < 2.5 x ULN (unless bone metastasis is present in the absence of liver metastasis, in which case 3.0 x ULN would be acceptable. h) Serum magnesium > 1.8 mg/dL i) Serum creatinine < 1.5 mg/dl j) Serum potassium > 3.8 mmol/L
  7. Tumor negative for HER2 expression (0 or 1+ by IHC) or negative FISH testing
  8. Patients must have a life expectancy of at least 12 weeks
  9. Patients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapy
  10. Patients must have < Grade 2 pre-existing peripheral neuropathy per CTCAE
  11. Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
  12. Negative serum or urine β-hCG pregnancy test at screening, performed no more than 72 hours prior to treatment initiation; for patients of childbearing potential
  13. Ability to understand and willingness to sign a written informed consent and HIPAA consent document

Exclusion Criteria:

  1. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse event from agents administered more than 4 weeks earlier
  2. Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
  3. Patients who have previously received romidepsin or Abraxane
  4. Patients with untreated or uncontrolled brain metastases or leptomeningeal disease
  5. Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  7. Any known cardiac abnormalities such as:

    1. Congenital long QT syndrome
    2. QTc interval ≥ 500 milliseconds
    3. Myocardial infarction within 6 months of C1D1. Subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
    4. Other significant EKG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)
    5. Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see Appendix III) In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
    6. An EKG recorded at screening showing evidence of cardiac ischemia (ST depression depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
    7. Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix IV) and/or known ejection fraction <40% by MUGA or <50% by echocardiogram and/orMRI
    8. A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
    9. Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
    10. Uncontrolled hypertension, i.e., blood pressure (BP) of ≥ 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria
    11. Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
    12. Patients taking drugs leading to significant QT prolongation (See Appendix I: Medications That May Cause QTc Prolongation)
    13. Concomitant use of CYP3A4 inhibitors (see Appendix II)
  8. Patients with known HIV, hepatitis B or C (However, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)
  9. Pregnant or breast feeding. Refer to section 4.4 for further detail
  10. Patients with any other medical or psychological condition deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01938833

Layout table for location information
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Sidney Kimmel Cancer Center at Thomas Jefferson University
Celgene Corporation
Layout table for investigator information
Principal Investigator: Maysa Abu-khalaf, MD Thomas Jefferson University
Additional Information:
Desai N, Trieu V, Yao R, et al. Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: a pathway inhibited by Taxol. Eur J Cancer Suppl. 2004;2:182.

Layout table for additonal information
Responsible Party: Sidney Kimmel Cancer Center at Thomas Jefferson University Identifier: NCT01938833    
Other Study ID Numbers: 13C.387
2013-035 ( Other Identifier: CCRRC )
First Posted: September 10, 2013    Key Record Dates
Results First Posted: September 29, 2017
Last Update Posted: December 28, 2017
Last Verified: December 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Breast Neoplasms, Male
Inflammatory Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic